---
schema_version: "secwatch.filing_event.v1"
accession: "0001326190-25-000024"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2025-03-13T23:59:59+00:00"
generated_at: "2026-05-24T20:31:30.649636+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Altimmune to pursue two new indications for pemvidutide: AUD and ALD, Phase 2 trials starting Q2/Q3 2025

## Summary
- Phase 2 AUD trial for pemvidutide targeting moderate to severe AUD; ~100 subjects, 24 weeks, endpoints include heavy drinking days.
- Phase 2 ALD trial for pemvidutide targeting obesity and ALD; ~100 subjects, 48 weeks, endpoints include liver stiffness and biomarkers.
- Both Phase 2 trials are randomized, double-blind, placebo-controlled designs.
- Altimmune expects to begin the AUD trial in Q2 2025 and the ALD trial in Q3 2025.

## SEC filing metadata
- accession: 0001326190-25-000024
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2025-03-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000132619025000024/0001326190-25-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000132619025000024/alt-20250313x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326190-25-000024
- JSON: https://secwatch.observer/filing/0001326190-25-000024.json
- Plain text: https://secwatch.observer/filing/0001326190-25-000024.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.